Ou Bai

Oubio (Suzhou) Biopharmaceutical is a biotechnology company focused on the development of circular RNA (circRNA) therapeutics and vaccines. Founded in 2021 and based in Suzhou, China, the company leverages its proprietary platform to design and manufacture circRNA, which offers superior stability and longer-lasting protein expression compared to traditional linear mRNA. Oubio's research is primarily directed toward creating effective solutions for infectious diseases and oncology. The company's technology suite includes advanced RNA circularization techniques and optimized lipid nanoparticle delivery systems. Supported by prominent investors such as Matrix Partners China, Oubio is advancing its pre-clinical pipeline toward human clinical trials to address significant unmet medical needs.